Glaukos Corporation, Allergan and Ivantis, Inc. are Dominating the USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market in 2019

USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market is expected to grow with the CAGR of 32.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/usa-micro-invasive-glaucoma-surgery-migs-devices-market

USA micro invasive glaucoma surgery (MIGS) devices market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the USA micro invasive glaucoma surgery (MIGS) devices market are introducing strong range of products provider along with launching new services and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced service portfolio.

The Glaukos Corporation is the dominating player in USA Micro invasive glaucoma surgery (MIGS) devices market. The other key players existing in the market includes Allergan, Ivantis, Inc., Ellex (Nova Eye Medical), Alcon, BVI, Johnson and Johnson Surgical Vision, Inc., MicroSurgical Technology, MOLTENO Ophthalmic Ltd, New World Medical, Inc., Santen Pharmaceutical Co., Ltd., and Sight Sciences among others.

USA Micro Invasive Glaucoma Surgery (MIGS) Devices MarketGlaukos Corporation

Glaukos Corporation is headquartered in California, U.S. and was founded in 1998. The company's focus is to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases. The company has business segments such as glaucoma, corneal health among which glaucoma is the market focussed segment, and they provide products such as glaucoma, corneal health, retinal Disease among which the market focussed product category is glaucoma.

For instance,

  • In June 2018, Glaukos Corporation announced that it has completed the patient enrolment for IDE trial of iStent infinite Trabecular Micro-Bypass System. It is used as a standalone procedure and is used to reduce elevated intra ocular pressure. The product launched led to increased revenue generation for the company.

The company has a wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such Avedro, Inc. (U.S.), Glaukos Europe GmbH (Europe), Glaukos Canada Inc. (Canada) and SASU France Glaukos (France) among others.

Allergan

Allergan is headquartered in Dunlin, Ireland and was founded in 2013. The company is focused on developing, manufacturing, commercializing the branded pharmaceutical device, biologic, surgical and regenerative medicine products for patients around the world. The company is dealing with the business segments such as US specialized therapeutics, US general medicine, international and others among which the market focussed segment is US specialized therapeutics. The company is providing the product categories such as central nervous system, eye care, gastroenterology, and medical aesthetics among which eye care is the market focused category.

For instance,

  • In April 2020, Allergan announced that China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN Gel Stent for the patients suffering from refractory glaucoma. As this is the first product to get the approval in China, which will lead to increased revenue generation in the market.

The company has a wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such as ZELTIQ Aesthetics (U.S.), ALLERGAN LIMITED (U.K), Envy Medical, Inc. (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.) and Actavis Group ehf (Iceland) among others.

Ivantis, Inc.

Ivantis, Inc. is headquartered in California, U.S. The company is focused on expanding patient treatment and improving outcomes through innovative minimally invasive glaucoma surgical (MIGS) solutions. The company is providing product such as hydrus microstent.

For instance,

  • In October 2019 Ivantis, Inc. announced the completion of enrollment of International SPECTRUM Registry for hydrus microstent. This completion could be provided as an insightful complement to their level 1 controlled trial publications. Hence, this product was preferred more and the revenue was also increased.

The company has a wide presence across North America, Europe, and Asia-Pacific.